UK PHARMACEUTICAL PRODUCTS MARKET RESEARCH REPORT

Table of Contents

1. EXECUTIVE SUMMARY

2. INTRODUCTION

• 2.1 Definitions
• 2.2 Abbreviations
• 2.3 Market Positioning
• 2.4 UK Economy
• 2.5 Market Factors

3. MARKET SIZE AND TRENDS

• 3.1 Chapter Summary
• 3.2 Market Size
• 3.3 Market Segmentation
  • 3.3.1 Prescription Medicines
  • 3.3.2 OTC Medicines
• 3.4 Market Trends
  • 3.4.1 Demographics
  • 3.4.2 Expenditure
  • 3.4.3 Generics
  • 3.4.4 Outsourcing
  • 3.4.5 Parallel Trade
  • 3.4.6 Herbal Medicines

4. SUPPLY SOURCES

• 4.1 Chapter Summary
• 4.2 Production
  • 4.2.1 Overview
  • 4.2.2 Segmentation
• 4.3 Imports
  • 4.3.1 Overview
  • 4.3.2 Segmentation
• 4.4 Exports
  • 4.4.1 Overview
  • 4.4.2 Segmentation
• 4.5 Trade Surplus/Deficit

5. INDUSTRY STRUCTURE

• 5.1 Chapter Summary
• 5.2 Industry Development
• 5.3 Structure by Employment
• 5.4 Structure by Turnover
• 5.5 Company Profiles
  • 5.5.1 American Home Products Holdings (UK)
  • 5.5.2 Amersham
  • 5.5.3 AstraZeneca
  • 5.5.4 Bristol-Myers Squibb Pharmaceuticals
  • 5.5.5 Celltech Group
  • 5.5.6 Eli Lilly & Co
  • 5.5.7 GlaxoSmithKline
  • 5.5.8 Johnson & Johnson
  • 5.5.9 Merck
  • 5.5.10 Merial
  • 5.5.11 Novartis UK
  • 5.5.12 Pfizer
  • 5.5.13 Pharmacia
  • 5.5.14 Roche Products
  • 5.5.15 Shire Pharmaceuticals Group
  • 5.5.16 Unichem

6. FORECAST

• 6.1 Chapter Summary
• 6.2 Market Size
• 6.3 Market Segmentation
• 6.4 Production
• 6.5 Imports
• 6.6 Industry

7. FURTHER SOURCES & CONTACTS

• 7.1 Trade Associations
• 7.2 Trade Magazines
• 7.3 Trade Exhibitions

List of Tables

• 1: UK Market for Pharmaceutical Products, 1998-2002
• 2: Segmentation of the UK Market for Pharmaceutical Products, 1998-2002
• 3: Segmentation of the UK Market for Pharmaceutical Products, 1998-2002
• 4: Number of Prescription Items Dispensed in the UK Market, by Country, 1997-2001
• 5: Prescription Items Dispensed in the UK Market, by Disease, 2001
• 6: UK Market for OTC Pharmaceutical Products and Top Branded Sellers, by Therapeutic Category, 2002
• 7: UK Population, by Age Group, 1981-2021
• 8: NHS Expenditure on Medicines in the UK, 1998-2002
• 9: UK Production of Pharmaceutical Products, 1998-2002
• 10: Segmentation of the UK Production of Pharmaceutical Products, by Type, 1998-2002
• 11: UK Imports of Pharmaceutical Products, 1998-2002
• 12: Segmentation of UK Imports of Pharmaceutical Products, by Type, 1998-2002
• 13: UK Exports of Pharmaceutical Products, 1998-2002
• 14: Segmentation of UK Exports of Pharmaceutical Products, by Type, 1998-2002
• 15: Analysis of the Changes in the Structure of the Basic Pharmaceuticals Manufacturing Industry, 1998-2002
• 16: Analysis of the Changes in the Structure of the Pharmaceutical Preparations Manufacturing Industry, 1998-2002
• 17: Analysis of the Employment Structure of the Basic Pharmaceuticals Manufacturing Industry, 2001 and 2002
• 18: Analysis of the Employment Structure of the Pharmaceutical Preparations Manufacturing Industry, 2001 and 2002
• 19: Analysis of the Financial Structure of the Basic Pharmaceuticals Manufacturing Sector, 2001 and 2002
• 20: Analysis of the Financial Structure of the Pharmaceutical Preparations Manufacturing Sector, 2001 and 2002
• 21: Financial Analysis of American Home Products Holdings (UK), 1997-2001
• 22: Key Financial Ratios for American Home Products Holdings (UK), 2000-2001
• 23: Financial Analysis of Amersham, 1997-2001
• 24: Key Financial Ratios for Amersham, 2000-2001
• 25: Financial Analysis of AstraZeneca, 1997-2001
• 26: Key Financial Ratios for AstraZeneca, 2000-2001
• 27: Financial Analysis of Bristol-Myers Squibb Pharmaceuticals, 1997-2001
• 28: Key Financial Ratios for Bristol-Myers Squibb Pharmaceuticals, 2000-2001
• 29: Financial Analysis of Celltech Group, 1997-2001
• 30: Key Financial Ratios for Celltech Group, 2000-2001
• 31: Financial Analysis of Eli Lilly & Company, 1997-2001
• 32: Key Financial Ratios for Eli Lilly & Co, 2000-2001
• 33: Financial Analysis of GlaxoSmithKline, 2000-2001
• 34: Key Financial Ratios for GlaxoSmithKline, 2000-2001
• 35: Financial Analysis of Johnson & Johnson, 1997-2001
• 36: Key Financial Ratios for Johnson & Johnson, 2000-2001
• 37: Financial Analysis of Merck, 1997-2001
• 38: Analysis of Merck Turnover, by Activity, 1997-2001
• 39: Key Financial Ratios for Merck, 2000-2001
• 40: Financial Analysis of Merial, 1997-2001
• 41: Key Financial Ratios for Merial, 2000-2001
• 42: Financial Analysis of Novartis UK, 1997-2001
• 43: Key Financial Ratios for Novartis UK, 2000-2001
• 44: Financial Analysis of Pfizer, 1997-2001
• 45: Key Financial Ratios for Pfizer, 2000-2001
• 46: Financial Analysis of Pharmacia, 1997-2001
• 47: Key Financial Ratios for Pharmacia, 2000-2001
• 48: Financial Analysis of Roche Products, 1997-2001
• 49: Key Financial Ratios for Roche Products, 2000-2001
• 50: Financial Analysis of Shire Pharmaceuticals Group, 1997-2001
• 51: Key Financial Ratios for Shire Pharmaceuticals Group, 2000-2001
• 52: Financial Analysis of Unichem, 1999-2001
• 53: Key Financial Ratios for Unichem, 2000-2001
• 54: Forecast UK Market for Pharmaceutical Products, 2003-2007
• 55: Forecast Segmentation of the UK Market for Pharmaceutical Products, 2003-2007
• 56: Forecast UK Production of Pharmaceutical Products, 2003-2007
• 57: Forecast UK Imports of Pharmaceutical Products, 2003-2007